21:43 , Oct 26, 2018 |  BioCentury  |  Finance

Springing into Cerevel

Bain Capital is following the blueprint for Pfizer Inc. (NYSE:PFE) spinout SpringWorks Therapeutics LLC and applying it on a larger scale to Cerevel Therapeutics LLC, which will develop Pfizer’s discontinued neuroscience pipeline with $350 million...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Mouse model of intellectual disability involving non-POU domain containing octamer-binding (NONO; NMT55) mutations

Disease models GABA A receptor GABRA2 gephyrin (GPHN) non-POU domain containing octamer-binding NMT55 University of Zurich...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models A mouse model of schizophrenia involving disruption of GABAA receptor clustering Mice with disrupted clustering of GABAA receptors could provide a...